



VII Congresso
Novas Fronteiras
em Cardiologia

17 de Fevereiro 2017

Aula Magna da Faculdade
de Medicina da Universidade
de Lisboa

18 e 19 de Fevereiro 2017

Hotel Marriott Praia Del-Rey

O CHLN em Números


Intervenção Estrutural

Miguel Nobre Menezes, Ana Rita Francisco, Pedro Carrilho Ferreira

O CHLN em números

O que fazemos

■ 2015 ■ 2016




O CHLN em números

O que fazemos

- Válvula aórtica percutânea - TAVI
- Valvuloplastia aórtica com balão
- Comissurotomia mitral percutânea
- Reparação percutânea mitral com clip
- Encerramento de leaks perivalvulares
- Encerramento de apêndice auricular, CIA e FOP
- Desnervação renal

O CHLN em números

O que fazemos



O CHLN em números

O que fazemos

- **Válvula aórtica percutânea - TAVI**
- Valvuloplastia aórtica com balão
- Comissurotomia mitral percutânea
- Reparação percutânea mitral com clip
- Encerramento de leaks perivalvulares
- Encerramento de apêndice auricular, CIA e FOP
- Desnervação renal

O CHLN em números

TAVI: População Basal

Variáveis	N = 238
Idade	81 $\pm$ 7
Sexo masculino	53%
IMC	25 $\pm$ 9
FEVE < 50%	20%
Gradiente Médio	52 $\pm$ 16
Área Valvular Aórtica	0,8 $\pm$ 0,2
NYHA	2,8 $\pm$ 0,5
II	23%
III	72%
IV	5%

Variáveis	N = 238
STS Score	6,8 $\pm$ 5,6
EuroSCORE II	4,5 $\pm$ 3,3
Doença coronária	39%
Antecedentes de ICP	30%
Fibrilhação auricular	24%
Diabetes mellitus	30%
Doença pulmonar crónica	29%
Doença vascular periférica	18%
Doença renal crónica	37%

O CHLN em números

TAVI: Procedimento

Transfemoral

- 93%
- $n=220$


Transapical

- 6%
- $n=16$

Transaórtica


- 1%
- $n=2$

■ Sapien XT® ■ Sapien 3® ■ CoreValve®
■ Evolut R® ■ Lotus® ■ Portico®




O CHLN em números

TAVI: Resultado imediato, complicações e pacemaker




O CHLN em números

TAVI: mortalidade




O CHLN em números

TAVI: mortalidade




O CHLN em números

TAV: mortalidade



O CHLN em números


TAVI: classe NYHA



Nenhum doente em classe NYHA $\geq$ III 73% em NYHA I


O CHLN em números

TAVI: acesso



O CHLN em números

TAVI: AVC



Para AVC major HR 5,9 IC 95% 2,3 – 15,1 $p < 0,001$

O CHLN em números

O que fazemos

- Válvula aórtica percutânea - TAVI
- Valvuloplastia aórtica com balão
- Comissurotomia mitral percutânea
- **Reparação percutânea mitral com clip**
- Encerramento de leaks perivalvulares
- Encerramento de apêndice auricular, CIA e FOP
- Desnervação renal


O CHLN em números

MitraClip: População Basal

- 33 doentes com regurgitação mitral grave



- FEVE média 39 ± 17 %

- Taxa de sucesso 97%



O CHLN em números

MitraClip: Impacto Sintomático




O CHLN em números

MitraClip: Impacto Prognóstico



O CHLN em números

MitraClip: Impacto Prognóstico segundo score 3C-HF



O CHLN em números

Actividade Científica

DAL-GENE - A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

GLOBAL LEADERS - Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and BioMatrix family drug-eluting stent use.

RE-DUAL PCI - A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus dopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAf) that have undergone a percutaneous coronary intervention (PCI) with stenting.

ENTRUST-AF - Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen in subjects with atrial fibrillation following successful percutaneous coronary intervention with stent placement. (Edoxaban treatment versus VKA in patients with AF undergoing PCI - ENTRUST-AF PCI)

AUGUSTUS - An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention

AMI-IC - A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment of patients with ST-elevation myocardial infarction.

RESHAPE-HF2 - A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation

COMPLETE - Randomized Comparative Effectiveness Study of Complete vs Culprit-only Revascularization Strategies to Treat Multi-vessel Disease After Primary Percutaneous Coronary Intervention (PCI) for ST-segment Elevation Myocardial (STEMI) Infarction

ISCHEMIA CKD - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches—Chronic Kidney Disease

PIONEER - SINOMED - Prospective, multi-center, randomized First-In-Man trial to compare the safety and efficacy of BuMA Supreme eG (Electro Grafting) based biodegradable polymer Sirolimus-eluting stent against Resolute Integrity Zotarolimus-eluting durable polymer stent in patients with de novo coronary artery lesions

FLAIR - Functional Lesion Assessment of Intermediate stenosis to guide Revascularisation (DEFINE-FLAIR)

AMULET - AMPLATZER TM Amulet TM Left Atrial Appendage Occluder

MASTER DAPT - Management of high bleeding risk patients post bioresorbable polymer coated STent implantation with an abbreviated versus prolonged DAPT regimen – MASTER DAPT

LL CardioArt ECHO vs. RHC protocol - Validation of a novel non-invasive hemodynamics algorithm
ULTIMASTER - Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice

MILES - Global: Post Marketing, Multicenter, Single Arm, Observational Clinical Registry to Evaluate Safety and Efficacy of BioMime Sirolimus Eluting Stent System In All Comers Real World Population With Coronary Artery Stenosis

FALCON - Falcon all comers DE-Ballon Registry

REPARA - Register of patients with bioresorbable device in daily clinical practice

EWOLUTION - Registry on WATCHMAN Outcomes in Real-Life Utilization

EnlightN - **EnlightN** European Observational Study

SYMPPLICITY - Global Prospective Registry for Sympathetic Renal Denervation In Selected Individuals Through 3-5 Years Registry

TAVI-LAAC - Combined transcatheter aortic valve implantation and percutaneous closure of the left atrial appendage

BIOSOLVE IV - Safety and Performance in de novo Lesion of Native Coronary Arteries With Magmaris- Registry

Coroflex ISAR - Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study

PRESSUREwire - Practical Evaluation of Fractional Flow Reserve (FFR) and its Associated Alternate Indices During Routine Clinical Procedures

O CHLN em números

Actividade Científica

- 7ª Reunião Anual da APIC 2016
 - 18 comunicações orais
- EuroPCR 2016
 - 15 comunicações orais, 3 posters
- TCT 2016
 - 1 comunicação oral, 5 posters moderados
- Publicações
 - Nobre Menezes M *et al*, Subacute Retrograde TAVI Migration Successfully Treated with a Valve-in-Valve Rev Esp Cardiol (Engl Ed). 2016 Sep 15. doi: 10.1016/j.rec.2016.08.003. [Epub ahead of print]
 - Boersma LV *et al*, Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016 Aug;37(31):2465-74